If this woman’s tumor overexpressed HER2, today’s oncologist would be able to employ a treatment such as trastuzumab, a humanized monoclonal antibody that blocks HER2 activity [14], in addition to systemic chemotherapy. The gene discussed is ERBB2; the disease is neoplasm.